VIDEO: Translational studies may ‘move the field forward’ in rheumatoid arthritis

ByJeffrey A. Sparks, MD, MMSc

ByMarley V. Ghizzone

Fact checked byKatrina Altersitz

WASHINGTON — In this video, Jeffrey A. Sparks, MD, MMSc, discusses two translational studies focused on human tissue for the treatment of rheumatoid arthritis.

The data were presented at ACR Convergence 2024.

“I think in concert, both of these translational abstracts really move the field forward and hopefully can find new drug targets,” Sparks, an associate professor of medicine at Harvard Medical School and an associate program director of the Rheumatology Fellowship, director of Immuno-Oncology and Autoimmunity and director of the Joint Biology Consortium Human Biosamples Core at Brigham and Women’s Hospital, told Healio.

Reference:

Korsunksy I, et al. Abstract #1664. Presented at: ACR Convergence 2024; Nov. 14-19, 2024; Washington, D.C.
Mueller A, et al. Abstract #2531. Presented at: ACR Convergence 2024; Nov. 14-19, 2024; Washington, D.C

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures: Sparks reports receiving research support from Boehringer Ingelheim, Bristol Myers Squibb, Johnson & Johnson, and Sonoma Biotherapeutics; and serving as a consultant for AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Fresenius Kabi, Gilead Sciences, Inova Diagnostics, Johnson & Johnson, Merck, MustangBio, Novartis, Optum, Pfizer, ReCor, Sana, Sobi, and UCB.

Discoveries in Rheumatoid Arthritis

Read more

VIDEO: Translational studies may ‘move the field forward’ in rheumatoid arthritis

Reference:

Related Content